Ajuf'ev B N, Dizhe E B, Efremov A M, Mogilenko D A, Oleĭnikova G N, Lapikov I A, Zhdanova O Iu, Kidgotko O V, Orlov S V, Perevozchikov A P
Mol Biol (Mosk). 2004 Nov-Dec;38(6):1076-84.
Human apolipoprotein A-I gene (apoA-I) plasmid expression vectors were transferred into mice by hydrodynamic injections into tail vein. Two types of expression vectors were used. First one -pCMVcapoAI contains cDNA of apo A-I driven by human cytomegalovirus early gene promoter (CMV). Second one--pAlg contains genomic locus of intron-containing apo A-I under control of own extended 5'-regulatory region (APOAI). Hydrodynamic intravenous injections of both expression vectors led to appearance of human apo A-I mRNA in the liver and human Apo A-I protein in the serum of injected mice. Dynamics of human Apo A-I content in the serum of mice injected by pCMVcapoAI and pAlg were different. When pCMVcapoAI was used, maximal concentration of human Apo A-I protein in the mouse serum was detected one day after injection with following decline to zero level during next two weeks. Under the same conditions injections of pAlg led to maximal level of human Apo A-I concentration in the mouse serum (up to 20 mkg/ml in some animals) on the 5th-7th day of experiment with following graduate decline during several months (human Apo A-I concentration in the serum of oldest analyzed mouse (6 months after injection) was about 25% of its maximal level in the same animal). Levels of human Apo A-I concentration in the mouse serum were compatible after injections of both expression vectors, in spite of much more strong activity of CMV promoter in comparison with APOAI in cultured human hepatoma cells HepG2. We ascribe the revealed difference in dynamics of human Apo A-I expression to delay of apo A-I transcription from pAlg vector, that was confirmed by nested RT-PCR. Significant level and long-term persistence of human Apo A-I in the serum of mice injected by pAlg could be explained by properties of APOAI or (and) exon-intron structure of genomic apo A-I gene. To test the role of APOAI in long-term expression of human Apo A-I in the mice we performed hydrodynamic injections of plasmid vectors containing cDNA of reporter gene encoding luciferase driven by variants of APOAI. No long-term expression of luciferase was found in the livers of injected mice. Therefore, our data suggest the role of exon-intron structure in maintaining of efficient and long-term expression of transferred human apo A-I.
通过尾静脉水动力注射将人载脂蛋白A-I基因(apoA-I)质粒表达载体导入小鼠体内。使用了两种类型的表达载体。第一种——pCMVcapoAI,包含由人巨细胞病毒早期基因启动子(CMV)驱动的apo A-I cDNA。第二种——pAlg,包含在自身延伸的5'-调控区(APOAI)控制下的含内含子的apo A-I基因组位点。两种表达载体的水动力静脉注射均导致注射小鼠肝脏中出现人apo A-I mRNA,血清中出现人Apo A-I蛋白。用pCMVcapoAI和pAlg注射的小鼠血清中人Apo A-I含量的动态变化不同。当使用pCMVcapoAI时,在注射后一天检测到小鼠血清中人Apo A-I蛋白的最大浓度,随后在接下来的两周内降至零水平。在相同条件下,注射pAlg导致在实验的第5至7天小鼠血清中人Apo A-I浓度达到最高水平(某些动物中高达20μg/ml),随后在几个月内逐渐下降(注射后6个月的最老分析小鼠血清中人Apo A-I浓度约为其在同一动物中最大水平的25%)。尽管与培养的人肝癌细胞HepG2中的APOAI相比,CMV启动子的活性要强得多,但注射两种表达载体后小鼠血清中人Apo A-I浓度水平相当。我们将人Apo A-I表达动态中发现的差异归因于pAlg载体中apo A-I转录的延迟,这通过巢式RT-PCR得到证实。pAlg注射的小鼠血清中人Apo A-I的显著水平和长期持续存在可以通过APOAI的特性或(和)基因组apo A-I基因的外显子-内含子结构来解释。为了测试APOAI在人Apo A-I在小鼠中的长期表达中的作用,我们进行了水动力注射含有由APOAI变体驱动的编码荧光素酶的报告基因cDNA的质粒载体。在注射小鼠的肝脏中未发现荧光素酶的长期表达。因此,我们的数据表明外显子-内含子结构在维持转移的人apo A-I的高效和长期表达中的作用。